Lentiviral vectors are used by Orchard to manufacture ex-vivo gene therapy products.
These products are used in primary immune deficiency disorders and inherited metabolic disorders, including adenosine deaminase severe combined immunodeficiency (ADA-SCID).
Adenosine deaminase deficiency is an inherited disorder, which damages the immune system and results in severe combined immunodeficiency.
Orchard will lead the global clinical development and commercialisation of collaboration programmes in Europe, the US and other regions under an exclusive intellectual property licence.
Under the agreement, Oxford BioMedica will have a 1.95% equity stake in Orchard and royalties on specific future product sales.
It will also provide process development services and manufacture commercial lentiviral vectors for Orchard.